The atherosclerotic process and its exacerbation by diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Baumgartl, H J ^a   Standl, E ^a  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

Author keywords

Atherosclerosis; Diabetes mellitus; Heparan sulfate proteo glycan (HSPG) Advanced glycosylation endproducts (AGEs); Microalbuminuria

Indexed keywords

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; INSULIN SENSITIVITY; MICROALBUMINURIA; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, CARDIOVASCULAR;

EID: 0034978303     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18604     Document Type: Article

References (38)

1. Diabetes mellitus and macrovascular complications: An epidemiological perspective
2. The pathogenesis of atherosclerosis-an update
3. Hyperinsulinaemia as an independent risk factor for ischaemic heart disease
4. Das metabolische Syndrom als potenter kardiovaskulärer Risikofaktor für vorzeitigen Tod bei Typ-II-Diabetikern. Die Schwabinger Studie II. Untersuchungen nach 9 Jahren
5. Häufigkeit, Risikoprofil und Letalitätsrate einer Stichprobe von Typ-II Diabetikern mit Albuminurie in der ärztlichen Praxis. Eine prospektive 5-Jahres-Verlaufsuntersuchung
6. The effect of intensaive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
7. Intensive blood glucose control with sulphonyl-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics). II: Asscociated risk factors
9. Risk profile of macrovascular disease in diabetes mellitus
10. Relationship between blood pressure and urinary albumin excretion in the development of microalbuminuria
11. Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the Greater Munich Area
12. Advanced Glycosylation Endproducts: Role in Diabetic and non-Diabetic Vasculare Disease
13. Advanced glycosylation endproducts in patients with diabetic nephropathy
14. Advanced glycosylation endproducts: Role in diabetic complications
15. Advanced Glycosylation Endproducts in patients with diabetic nephropathy
16. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo
17. Cachetin/TNF and IL1 induced by glucose-modified proteins: Role in normal tissue remodeling
18. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
19. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
20. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
21. Advanced glycation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes
22. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
23. Expressions of transforming growth factor beta is elevated in human and experimental diabetic nephropathy
24. Upregulation of myoinositol transport compensates for competitive inhibition by glucose
25. High glucose increases diacylglycerol mass and activates protein C in mesangial cells
26. Distribution of glycosaminoglycan in the intima of human aortas: Changes in atherosklerosis and diabetes mellitus
27. Microalbuminuria: Implication for micro-and macrovascular disease
28. An open, controlled study of sulodexide therapie for the treatment of diabetic nephropathy
29. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats
30. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
31. Effect of high glucose on type IV collagen production by cultured glomerular epithelial, endothelial and mesangial cells
32. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen
33. Expression of angiogenetic growth factors in diabetic neovascular membranes
34. Hypoxic regulation of vascular permeability factor (vascular endothelial groth factor) mRNA and protein secretion by human retinal pigment epithelial cells
35. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis
36. Research methodologies in measurement of platelet functions, endothelial proteins, coagulation factors and fibrinolysis
37. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM
38. Diabetes mellitus: A disease of abnormal cellular calcium metabolism?